Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy

NCT01215097 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

306

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Linagliptin
DRUG: placebo

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]